Current methods for identifying plasma membrane proteins as cancer biomarkers
E Jong, A Kocer - Membranes, 2023 - mdpi.com
Plasma membrane proteins are a special class of biomolecules present on the cellular
membrane. They provide the transport of ions, small molecules, and water in response to …
membrane. They provide the transport of ions, small molecules, and water in response to …
Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with non-small cell lung cancer carrying uncommon EGFR …
HS Li, SZ Wang, HY Xu, X Yan, JY Zhang, SY Lei, T Li… - Cancers, 2022 - mdpi.com
Simple Summary Afatinib has been approved for patients with lung cancer carrying
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
[HTML][HTML] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
SY Lee, CM Choi, YS Chang, KY Lee… - … lung cancer Research, 2021 - ncbi.nlm.nih.gov
Background We investigated the clinical characteristics and treatment outcomes of Korean
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
Cetuximab combined with sonodynamic therapy achieves dual-modal image monitoring for the treatment of EGFR-sensitive non-small-cell lung cancer
G Qiu, L Xue, X Zhu, X Lu, L Liu, Z Wang, X Li… - Frontiers in …, 2022 - frontiersin.org
Background Blocking signaling by epidermal growth factor receptor (EGFR), can effectively
inhibit the proliferation and differentiation of non-small-cell lung cancer (NSCLC) …
inhibit the proliferation and differentiation of non-small-cell lung cancer (NSCLC) …
Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
Y Lin, L Chen, R Li, X Liu, Q Li, J Cai, Y Du… - Frontiers in …, 2023 - frontiersin.org
Importance Patients with EGFR mutations who have advanced-stage non-small cell lung
cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line …
cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line …
[HTML][HTML] Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional …
WM Brueckl, M Reck, H Schäfer, K Neben… - Journal of Geriatric …, 2023 - Elsevier
Introduction Lung cancer is most common in older patients; despite this, older patients are
historically under-represented in clinical studies. Here we present data from GIDEON, a …
historically under-represented in clinical studies. Here we present data from GIDEON, a …
[HTML][HTML] Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer
GDM Veerman, DP Hurkmans, MS Paats… - Biomedicine & …, 2022 - Elsevier
Afatinib is an oral small-molecule kinase inhibitor (SMKI) approved for treatment of
metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor …
metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor …
[HTML][HTML] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
J Choi, CM Choi, YS Chang, KY Lee… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Data from clinical trials and real-world studies show that afatinib is effective in
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …
[HTML][HTML] Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
J Qian, X Ye, A Huang, R Qin, Y Cai, Y Xue… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background Afatinib 30 mg has been proved to be with comparable efficacy but more
tolerable than the dose of 40 mg for Asian patients with non-small cell lung cancer (NSCLC) …
tolerable than the dose of 40 mg for Asian patients with non-small cell lung cancer (NSCLC) …
[HTML][HTML] Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
J Kim, TW Jang, CM Choi, MH Kim, SY Lee… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and
brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain …
brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain …